Glenmark to outlicense one molecule in FY10

24 Dec 2009 Evaluate

Glenmark Pharmaceuticals is looking to out-license at least one molecule in fiscal 2010, probably Melogliptin. It is renegotiating a deal for the diabetes drug and is seeking a tie-up for anti-asthma drug Oglemilast for the European market. It is also looking to outlicense phase 2-b trials Oglemilast.

 

Outlicensing of Melogliptin and launch of Crofelmer (for HIV-related diarrhoea), which is a phase 3 candidate, are focus areas for Glenmark. A successful launch of Crofelmer can add $20-25 million annually to the company's net profit.

 

Meanwhile, Glenmark expects to launch Crofelmer across the world by the end of the next fiscal. The company is expecting sales of $80 million in the next 2-3 years as it will price the product at a premium to the currently available treatment options.

crackcrack

Glenmark Pharma Share Price

1388.15 66.80 (5.06%)
17-Feb-2025 13:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.00
Dr. Reddys Lab 1197.80
Cipla 1470.80
Lupin 2012.40
Zydus Lifesciences 923.10
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Loading...
Hold on